The real drug development delay? Bad communication.

Biotech’s old risk-sharing model is breaking down, forcing academia, investors, pharma, and healthcare systems to collaborate ...

“You could have the cure for cancer, but if you can’t execute, it doesn’t matter.” ...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced it has been named “Overall Immunology Company of the Year” in ...

WASHINGTON — Biotech breakthroughs are within U.S. reach, but policy shifts and proposed funding cuts could slow how those advancements reach patients, health organization leaders warned at an April ...

UC Santa Cruz deepens industry engagement to underscore its vital role in contributing basic research and tomorrow’s talent, convening its first international RNA biotech conference on August 18 ...

ALPS Medical Breakthroughs ETF (SBIO) targets late-stage clinical biotech firms poised for FDA approval or acquisition, offering high-risk, high-reward exposure. SBIO surged 91% over the past year, ...

The Beijing-based biotech company, METiS TechBio, debuted on TR50 this year, reflecting the promise of its NanoForge platform ...

The U.S. biotechnology industry is healthier than it has been in years—stock prices and mergers and acquisitions are surging and companies are making breakthroughs in diseases, such as pancreatic ...

South Korea’s seven-part technology strategy sets targets for a 2030 robotic Moon landing, quantum computing, energy, biotech, and critical materials.

The MarketWatch News Department was not involved in the creation of this content. In today's rapidly developing field of nanotechnology, Lazuriton Nano Biotechnology stands out in the global nano ...

BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced it has been named "Overall Immunology Company of the Year" in the fifth annual BioTech ...